3 days Ago By ABMN Staff
TriSalus Life Sciences, Inc. ( NASDAQ:TLSI – Get Free Report ) CEO Mary T. Szela acquired 7,520 shares of the stock in a transaction on Thursday, September 12th.
The shares were purchased at an average price of $5.20 per share, for a total transaction of $39,104.00.
Following the transaction, the chief executive officer now directly owns 377,382 shares in the company, valued at $1,962,386.40. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink .
TriSalus Life Sciences Stock Down 12.1 % Shares of NASDAQ TLSI opened at $4.52 on Monday.
The business has a fifty day moving average price of $5.49 and a two-hundred day moving average price of $7.46.
TriSalus Life Sciences, Inc. has a fifty-two week low of $3.32 and a fifty-two week high of $10.
42. TriSalus Life Sciences ( NASDAQ:TLSI – Get Free Report ) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.
21) EPS for the quarter. The company had revenue of $7.36 million during the quarter.
Analyst Upgrades and Downgrades Check Out Our Latest Research Report on TriSalus Life Sciences Hedge Funds Weigh In On TriSalus Life Sciences Hedge funds and other institutional investors have recently made changes to their positions in the company. Wolverine Asset Management LLC acquired a new stake in shares of TriSalus Life Sciences during the 2nd quarter worth approximately $240,000. Highbridge Capital Management LLC acquired a new position in TriSalus Life Sciences during the second quarter valued at approximately $1,184,000.
Finally, Duquesne Family Office LLC lifted its stake in TriSalus Life Sciences by 35.1% during the second quarter. Duquesne Family Office LLC now owns 426,921 shares of the company’s stock worth $2,357,000 after purchasing an additional 110,966 shares during the last quarter.
2.58% of the stock is currently owned by institutional investors and hedge funds. TriSalus Life Sciences Company Profile ( Get Free Report ) TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer.
The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. Recommended Stories Receive News & Ratings for TriSalus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TriSalus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter .
.
